{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:21Z","timestamp":1790701521508,"version":"4.1.0"},"reference-count":40,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In patients with epilepsy, treatment with valproate (VPA) has been reported to be associated with polycystic ovary syndrome-like symptoms including weight gain, hyperandrogenemia, and hyperinsulinemia. We examined the effect of VPA on androgen biosynthesis in ovarian theca cells isolated from follicles of normal cycling women to determine whether the hyperandrogenemia reported with VPA treatment could be a result of direct effects of VPA on the ovary. In long-term cultures of theca cells treated for 72 h with sodium valproate (30\u20133000 \u03bcm), we observed an increase in basal and forskolin-stimulated dehydroepiandrosterone (DHEA), androstenedione, and 17\u03b1-hydroxyprogesterone production compared with control values. In contrast, low doses of VPA treatment (i.e. 30\u2013300 \u03bcm) had no effect on basal and forskolin-stimulated progesterone production, whereas higher doses of VPA (1000\u20133000 \u03bcm) inhibited progesterone production. The most pronounced effect of VPA on androgen biosynthesis was observed in the dose range of 300-3000 \u03bcm, which represent therapeutic levels in the treatment of epilepsy and bipolar disorder. Western analyses demonstrated that VPA treatment increased both basal and forskolin-stimulated P450c17 and P450scc protein levels, whereas the amount of steroidogenic acute regulatory protein was unaffected. In transient transfection studies, VPA was found to increase P450 17\u03b1-hydroxylase and P450 cholesterol side-chain cleavage promoter activity, whereas steroidogenic acute regulatory protein promoter activity was unaffected. Consistent with the ability of VPA to act as a histone deacetylase (HDAC) inhibitor in other cell systems, VPA (500 \u03bcm) treatment was observed to increase histone H3 acetylation and P450 17\u03b1-hydroxylase mRNA accumulation. The HDAC inhibitor butyric acid (500 \u03bcm) similarly increased histone H3 acetylation and DHEA biosynthesis, whereas the VPA derivative valpromide (500 \u03bcm), which lacks HDAC inhibitory activity, had no effect on histone acetylation or DHEA biosynthesis. These data suggest that VPA-induced ovarian androgen biosynthesis results from changes in chromatin modifications (histone acetylation) that augment transcription of steroidogenic genes. These studies provide the first biochemical evidence to support a role for VPA in the genesis of polycystic ovary syndrome-like symptoms, and establish a direct link between VPA treatment and increased ovarian androgen biosynthesis.<\/jats:p>","DOI":"10.1210\/en.2003-0940","type":"journal-article","created":{"date-parts":[[2003,10,28]],"date-time":"2003-10-28T07:45:00Z","timestamp":1067327100000},"page":"799-808","source":"Crossref","is-referenced-by-count":141,"title":["Valproate Potentiates Androgen Biosynthesis in Human Ovarian Theca Cells"],"prefix":"10.1210","volume":"145","author":[{"given":"Velen L.","family":"Nelson-DeGrave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Wickenheisser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Cockrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Legro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome F.","family":"Strauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M.","family":"McAllister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071612483366700_R1","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jcem.86.7.7633","article-title":"Characterization of reproductive endocrine disorders in women with epilepsy.","volume":"86","author":"Bilo","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612483366700_R2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0920-1211(00)00139-X","article-title":"Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women.","volume":"41","author":"Bauer","year":"2000","journal-title":"Epilepsy Res"},{"key":"2020071612483366700_R3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJM199311043291904","article-title":"Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy.","volume":"329","author":"Isojarvi","year":"1993","journal-title":"N Engl J Med"},{"key":"2020071612483366700_R4","first-page":"52","article-title":"Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy.","volume":"21","author":"Murialdo","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"2020071612483366700_R5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/1531-8249(199904)45:4<444::AID-ANA5>3.0.CO;2-6","article-title":"Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy.","volume":"45","author":"Vainionpaa","year":"1999","journal-title":"Ann Neurol"},{"key":"2020071612483366700_R6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/088307380201700405","article-title":"Insulin resistance in epileptic girls who gain weight after therapy with valproic acid.","volume":"17","author":"Verrotti","year":"2002","journal-title":"J Child Neurol"},{"key":"2020071612483366700_R7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0887-8994(00)00133-8","article-title":"Weight gain associated with valproate in childhood.","volume":"22","author":"Demir","year":"2000","journal-title":"Pediatr Neurol"},{"key":"2020071612483366700_R8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(01)00806-3","article-title":"Altered ovarian function and cardiovascular risk factors in valproate-treated women.","volume":"111","author":"Isojarvi","year":"2001","journal-title":"Am J Med"},{"issue":"Suppl 3","key":"2020071612483366700_R9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1046\/j.1528-1157.2001.042suppl.3060.x","article-title":"Polycystic ovarian syndrome in women with epilepsy: a review","volume":"42","author":"Duncan","year":"2001","journal-title":"Epilepsia"},{"key":"2020071612483366700_R10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1034\/j.1399-5618.2003.00009.x","article-title":"Valproate, bipolar disorder and polycystic ovarian syndrome.","volume":"5","author":"McIntyre","year":"2003","journal-title":"Bipolar Disord"},{"key":"2020071612483366700_R11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1528-1157.2001.33500.x","article-title":"Valproate and the polycystic ovarian syndrome: final thoughts.","volume":"42","author":"Herzog","year":"2001","journal-title":"Epilepsia"},{"key":"2020071612483366700_R12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1528-1157.2001.28899.x","article-title":"On the association between valproate and polycystic ovary syndrome.","volume":"42","author":"Genton","year":"2001","journal-title":"Epilepsia"},{"key":"2020071612483366700_R13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0940-2993(01)80014-2","article-title":"Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats.","volume":"52","author":"Roste","year":"2001","journal-title":"Exp Toxicol Pathol"},{"key":"2020071612483366700_R14","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1210\/jc.2002-021614","article-title":"Endocrine and metabolic responses to long-term monotherapy with the antiepileptic drug valproate in the normally cycling rhesus monkey.","volume":"88","author":"Ferin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612483366700_R15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/seiz.2000.0443","article-title":"Valproate-induced alterations in testosterone, estradiol and progesterone secretion from porcine follicular cells isolated from small- and medium-sized ovarian follicles.","volume":"9","author":"Gregoraszczuk","year":"2000","journal-title":"Seizure"},{"key":"2020071612483366700_R16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0890-6238(02)00020-5","article-title":"Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro.","volume":"16","author":"Tauboll","year":"2002","journal-title":"Reprod Toxicol"},{"key":"2020071612483366700_R17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0006-8993(02)02362-4","article-title":"A role for protein kinase C and its substrates in the action of valproic acid in the brain: implications for neural plasticity.","volume":"934","author":"Watterson","year":"2002","journal-title":"Brain Res"},{"key":"2020071612483366700_R18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1046\/j.1471-4159.2000.0721327.x","article-title":"The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.","volume":"72","author":"Chen","year":"1999","journal-title":"J Neurochem"},{"key":"2020071612483366700_R19","doi-asserted-by":"crossref","first-page":"31674","DOI":"10.1074\/jbc.M104309200","article-title":"The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth.","volume":"276","author":"Yuan","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071612483366700_R20","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071612483366700_R21","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J"},{"key":"2020071612483366700_R22","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/mend.13.6.0311","article-title":"Augmented androgen production is a stable phenotype of propagated theca cells from polycystic ovaries.","volume":"13","author":"Nelson","year":"1999","journal-title":"Mol Endocrinol"},{"key":"2020071612483366700_R23","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1210\/jcem.86.12.8088","article-title":"The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome.","volume":"86","author":"Nelson","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612483366700_R24","first-page":"2304","article-title":"Differential activity of the cytochrome P450 17\u03b1-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells.","volume":"85","author":"Wickenheisser","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612483366700_R25","first-page":"330","author":"McAllister","year":"1993"},{"key":"2020071612483366700_R26","first-page":"377","author":"Zawadzki","year":"1992"},{"key":"2020071612483366700_R27","doi-asserted-by":"crossref","first-page":"14956","DOI":"10.1073\/pnas.95.25.14956","article-title":"Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.","volume":"95","author":"Legro","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071612483366700_R28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1046\/j.1523-1747.2003.12244.x","article-title":"Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1).","volume":"120","author":"Thiboutot","year":"2003","journal-title":"J Invest Dermatol"},{"key":"2020071612483366700_R29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1210\/jc.2002-021274","article-title":"Stromal cells of the human postmenopausal ovary display a distinctive biochemical and molecular phenotype.","volume":"88","author":"Jabara","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612483366700_R30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10409230091169177","article-title":"Ku autoantigen: a multifunctional DNA-binding protein.","volume":"35","author":"Tuteja","year":"2000","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2020071612483366700_R31","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1074\/jbc.274.9.5626","article-title":"MENT, a heterochromatin protein that mediates higher order chromatin folding, is a new serpin family member.","volume":"274","author":"Grigoryev","year":"1999","journal-title":"J Biol Chem"},{"key":"2020071612483366700_R32","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1074\/jbc.273.5.3082","article-title":"Chromatin structure in granulocytes. A link between tight compaction and accumulation of a heterochromatin-associated protein (MENT).","volume":"273","author":"Grigoryev","year":"1998","journal-title":"J Biol Chem"},{"key":"2020071612483366700_R33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0042-6822(73)90341-3","article-title":"A new technique for the assay of infectivity of human adenovirus 5.","volume":"52","author":"Graham","year":"1973","journal-title":"Virology"},{"key":"2020071612483366700_R34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1542\/peds.103.3.588","article-title":"The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy.","volume":"103","author":"Rattya","year":"1999","journal-title":"Pediatrics"},{"key":"2020071612483366700_R35","doi-asserted-by":"crossref","first-page":"26380","DOI":"10.1074\/jbc.M300688200","article-title":"The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis.","volume":"278","author":"Wood","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071612483366700_R36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.0.1740001","article-title":"Developmental origin of polycystic ovary syndrome\u2014a hypothesis.","volume":"174","author":"Abbott","year":"2002","journal-title":"J Endocrinol"},{"key":"2020071612483366700_R37","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0889-8529(05)70286-3","article-title":"Polycystic ovary syndrome.","volume":"26","author":"Goudas","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071612483366700_R38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF03349709","article-title":"The effect of sodium valproate on luteinizing hormone secretion in women with polycystic ovary disease.","volume":"18","author":"Popovic","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"2020071612483366700_R39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/archneur.57.7.1064","article-title":"Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases.","volume":"57","author":"Isojarvi","year":"2000","journal-title":"Arch Neurol"},{"key":"2020071612483366700_R40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4088\/JCP.v61n0305","article-title":"Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report.","volume":"61","author":"Rasgon","year":"2000","journal-title":"J Clin Psychiatry"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/145\/2\/799\/9023970\/endo0799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/145\/2\/799\/9023970\/endo0799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T21:57:55Z","timestamp":1594936675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/145\/2\/799\/2500492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2003-0940","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,1]]}}}